| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| General Surgery | 29 | 2024 | 1720 | 2.030 |
Why?
|
| Pancreatectomy | 18 | 2022 | 825 | 2.000 |
Why?
|
| Pancreatic Neoplasms | 54 | 2022 | 5444 | 1.890 |
Why?
|
| Jejunum | 29 | 2014 | 474 | 1.290 |
Why?
|
| Pancreatitis | 27 | 2013 | 1087 | 1.260 |
Why?
|
| Internship and Residency | 25 | 2024 | 5943 | 1.080 |
Why?
|
| Pancreatitis, Acute Necrotizing | 8 | 2014 | 174 | 1.050 |
Why?
|
| Laparoscopy | 13 | 2018 | 2039 | 1.030 |
Why?
|
| Hernia, Ventral | 4 | 2020 | 220 | 1.000 |
Why?
|
| Pancreaticoduodenectomy | 9 | 2020 | 515 | 0.990 |
Why?
|
| Intestine, Small | 19 | 2012 | 1217 | 0.980 |
Why?
|
| Education, Medical, Graduate | 8 | 2022 | 2418 | 0.930 |
Why?
|
| Sodium-Glucose Transporter 1 | 17 | 2014 | 108 | 0.930 |
Why?
|
| Vascular Surgical Procedures | 7 | 2018 | 1506 | 0.870 |
Why?
|
| Postoperative Care | 3 | 2016 | 1480 | 0.830 |
Why?
|
| Monosaccharide Transport Proteins | 12 | 2005 | 437 | 0.820 |
Why?
|
| Intestinal Absorption | 17 | 2011 | 400 | 0.790 |
Why?
|
| Sclerotherapy | 2 | 2014 | 183 | 0.770 |
Why?
|
| Pancreas | 25 | 2022 | 1698 | 0.750 |
Why?
|
| Clinical Competence | 13 | 2024 | 4858 | 0.750 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 49 | 2021 | 11872 | 0.700 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2018 | 584 | 0.700 |
Why?
|
| Peptides | 19 | 2005 | 4344 | 0.680 |
Why?
|
| Incidental Findings | 2 | 2016 | 698 | 0.680 |
Why?
|
| Operating Rooms | 7 | 2020 | 790 | 0.670 |
Why?
|
| Deoxycytidine | 14 | 2011 | 886 | 0.660 |
Why?
|
| Cystadenocarcinoma, Mucinous | 2 | 2015 | 51 | 0.650 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2016 | 1126 | 0.600 |
Why?
|
| Intestinal Mucosa | 20 | 2013 | 3041 | 0.600 |
Why?
|
| Postoperative Complications | 20 | 2020 | 15831 | 0.600 |
Why?
|
| Gastric Mucosa | 16 | 1989 | 602 | 0.590 |
Why?
|
| Neoadjuvant Therapy | 13 | 2021 | 2902 | 0.570 |
Why?
|
| Phlebotomy | 1 | 2017 | 138 | 0.550 |
Why?
|
| Specialties, Surgical | 6 | 2021 | 391 | 0.550 |
Why?
|
| Dumping Syndrome | 1 | 2016 | 22 | 0.550 |
Why?
|
| Gastrointestinal Hormones | 8 | 2004 | 101 | 0.550 |
Why?
|
| Hospitals | 4 | 2017 | 3888 | 0.540 |
Why?
|
| Pancreatic Ducts | 7 | 2012 | 330 | 0.540 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2016 | 23 | 0.530 |
Why?
|
| Medical Waste | 1 | 2016 | 16 | 0.530 |
Why?
|
| Medical Waste Disposal | 1 | 2016 | 14 | 0.530 |
Why?
|
| Blood Specimen Collection | 1 | 2017 | 238 | 0.530 |
Why?
|
| Adenocarcinoma | 29 | 2022 | 6359 | 0.520 |
Why?
|
| Ileum | 9 | 2008 | 558 | 0.520 |
Why?
|
| Hospital Costs | 3 | 2018 | 955 | 0.520 |
Why?
|
| Esophageal Motility Disorders | 1 | 2016 | 49 | 0.510 |
Why?
|
| Breast Neoplasms | 53 | 2015 | 21162 | 0.510 |
Why?
|
| Workload | 7 | 2017 | 849 | 0.510 |
Why?
|
| Humans | 335 | 2024 | 766766 | 0.510 |
Why?
|
| Surgical Mesh | 2 | 2016 | 315 | 0.500 |
Why?
|
| Certification | 2 | 2018 | 420 | 0.500 |
Why?
|
| Gastrointestinal Stromal Tumors | 4 | 2012 | 616 | 0.500 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2021 | 1757 | 0.490 |
Why?
|
| Laparotomy | 3 | 2015 | 459 | 0.490 |
Why?
|
| Gastric Emptying | 4 | 2016 | 247 | 0.490 |
Why?
|
| Adaptation, Physiological | 9 | 2005 | 1313 | 0.490 |
Why?
|
| Failure to Thrive | 1 | 2016 | 139 | 0.490 |
Why?
|
| Fluorouracil | 15 | 2011 | 1651 | 0.480 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2017 | 263 | 0.480 |
Why?
|
| Dehydration | 1 | 2016 | 216 | 0.460 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2016 | 215 | 0.460 |
Why?
|
| Female | 257 | 2022 | 396520 | 0.460 |
Why?
|
| Catheterization | 3 | 2017 | 1429 | 0.460 |
Why?
|
| Adrenal Medulla | 1 | 2014 | 56 | 0.460 |
Why?
|
| Varicose Ulcer | 1 | 2014 | 55 | 0.450 |
Why?
|
| Early Ambulation | 1 | 2014 | 49 | 0.450 |
Why?
|
| Denaturing Gradient Gel Electrophoresis | 1 | 2013 | 3 | 0.450 |
Why?
|
| Male | 205 | 2022 | 364142 | 0.440 |
Why?
|
| Limb Salvage | 1 | 2016 | 488 | 0.430 |
Why?
|
| Environmental Health | 1 | 2016 | 297 | 0.420 |
Why?
|
| Clodronic Acid | 5 | 1999 | 60 | 0.420 |
Why?
|
| Homicide | 1 | 2016 | 294 | 0.420 |
Why?
|
| Universities | 1 | 2018 | 1004 | 0.410 |
Why?
|
| Circadian Rhythm | 11 | 2013 | 2593 | 0.410 |
Why?
|
| Pylorus | 2 | 2011 | 86 | 0.410 |
Why?
|
| Neuroendocrine Tumors | 2 | 2018 | 659 | 0.400 |
Why?
|
| Diabetic Foot | 1 | 2016 | 383 | 0.400 |
Why?
|
| Survival Rate | 35 | 2021 | 12825 | 0.400 |
Why?
|
| Gallstones | 5 | 2022 | 285 | 0.400 |
Why?
|
| Aged | 153 | 2021 | 171343 | 0.390 |
Why?
|
| Treatment Outcome | 71 | 2018 | 65273 | 0.390 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2015 | 523 | 0.390 |
Why?
|
| Adrenalectomy | 1 | 2014 | 347 | 0.390 |
Why?
|
| Pheochromocytoma | 1 | 2014 | 327 | 0.380 |
Why?
|
| Sodium Tetradecyl Sulfate | 1 | 2011 | 14 | 0.380 |
Why?
|
| Cholecystectomy, Laparoscopic | 5 | 2015 | 236 | 0.380 |
Why?
|
| Peptic Ulcer | 2 | 2012 | 214 | 0.380 |
Why?
|
| Cystadenoma, Serous | 1 | 2012 | 99 | 0.370 |
Why?
|
| Leg | 3 | 2002 | 1087 | 0.370 |
Why?
|
| Antimetabolites, Antineoplastic | 9 | 2010 | 646 | 0.360 |
Why?
|
| Sclerosing Solutions | 1 | 2011 | 79 | 0.360 |
Why?
|
| Carcinoma, Papillary | 3 | 2015 | 791 | 0.360 |
Why?
|
| Work Schedule Tolerance | 4 | 2017 | 553 | 0.360 |
Why?
|
| Air | 1 | 2011 | 182 | 0.360 |
Why?
|
| Middle Aged | 165 | 2021 | 223257 | 0.350 |
Why?
|
| Gallbladder Neoplasms | 2 | 2010 | 190 | 0.350 |
Why?
|
| Strongyloidiasis | 1 | 2010 | 27 | 0.350 |
Why?
|
| Glucagon-Like Peptides | 9 | 2005 | 157 | 0.350 |
Why?
|
| Surgical Procedures, Operative | 7 | 2014 | 1931 | 0.340 |
Why?
|
| Gastric Bypass | 3 | 2014 | 820 | 0.340 |
Why?
|
| Jejunal Diseases | 1 | 2010 | 45 | 0.340 |
Why?
|
| Cell Adhesion Molecules | 10 | 2005 | 1612 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 20 | 2015 | 9404 | 0.330 |
Why?
|
| Duodenal Diseases | 1 | 2010 | 101 | 0.330 |
Why?
|
| Subliminal Stimulation | 1 | 2009 | 8 | 0.330 |
Why?
|
| Cholecystectomy | 6 | 2011 | 409 | 0.330 |
Why?
|
| Observer Variation | 1 | 2016 | 2614 | 0.330 |
Why?
|
| Schistosomiasis mansoni | 1 | 2010 | 94 | 0.330 |
Why?
|
| Education, Medical | 3 | 2020 | 1744 | 0.330 |
Why?
|
| Varicose Veins | 1 | 2011 | 158 | 0.330 |
Why?
|
| Survival Analysis | 40 | 2010 | 10100 | 0.320 |
Why?
|
| Patient Care Team | 2 | 2017 | 2519 | 0.320 |
Why?
|
| Costs and Cost Analysis | 4 | 2018 | 1667 | 0.320 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2013 | 1044 | 0.320 |
Why?
|
| Attitude of Health Personnel | 9 | 2021 | 3927 | 0.320 |
Why?
|
| Intestinal Obstruction | 2 | 2012 | 433 | 0.320 |
Why?
|
| Diverticulum | 1 | 2010 | 137 | 0.320 |
Why?
|
| Prognosis | 52 | 2021 | 29948 | 0.310 |
Why?
|
| Hernia, Inguinal | 1 | 2011 | 224 | 0.310 |
Why?
|
| Adult | 152 | 2020 | 223307 | 0.310 |
Why?
|
| Membrane Glycoproteins | 8 | 2004 | 3702 | 0.300 |
Why?
|
| Mesothelioma | 6 | 2011 | 774 | 0.300 |
Why?
|
| DNA, Bacterial | 1 | 2013 | 1477 | 0.300 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2014 | 732 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 19 | 2016 | 20708 | 0.300 |
Why?
|
| Aged, 80 and over | 60 | 2018 | 59550 | 0.300 |
Why?
|
| Carcinoid Tumor | 3 | 2006 | 225 | 0.300 |
Why?
|
| Antigens, Neoplasm | 10 | 2005 | 1998 | 0.300 |
Why?
|
| Saphenous Vein | 1 | 2011 | 519 | 0.300 |
Why?
|
| Carbon Dioxide | 3 | 2011 | 1138 | 0.290 |
Why?
|
| Learning | 3 | 2012 | 1754 | 0.290 |
Why?
|
| Neoplasm Invasiveness | 10 | 2008 | 3609 | 0.280 |
Why?
|
| Regenerative Medicine | 1 | 2011 | 304 | 0.280 |
Why?
|
| Electrolytes | 6 | 2001 | 279 | 0.280 |
Why?
|
| Hodgkin Disease | 9 | 2007 | 1384 | 0.280 |
Why?
|
| Societies, Medical | 2 | 2020 | 3957 | 0.280 |
Why?
|
| Patient Readmission | 4 | 2018 | 3283 | 0.270 |
Why?
|
| Glucagon-Like Peptide 2 | 8 | 2005 | 45 | 0.270 |
Why?
|
| Evidence-Based Medicine | 6 | 2014 | 3692 | 0.270 |
Why?
|
| Breast | 3 | 2015 | 1971 | 0.270 |
Why?
|
| Personnel Staffing and Scheduling | 5 | 2017 | 497 | 0.270 |
Why?
|
| Carotid Stenosis | 1 | 2014 | 858 | 0.270 |
Why?
|
| Bacteremia | 1 | 2013 | 987 | 0.260 |
Why?
|
| Education, Medical, Continuing | 4 | 2021 | 830 | 0.260 |
Why?
|
| Societies | 1 | 2006 | 106 | 0.260 |
Why?
|
| Lung Neoplasms | 18 | 2011 | 13485 | 0.260 |
Why?
|
| Intestines | 6 | 2008 | 1904 | 0.260 |
Why?
|
| Rats | 38 | 2014 | 23717 | 0.260 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2011 | 957 | 0.260 |
Why?
|
| State Medicine | 2 | 2009 | 219 | 0.260 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 3485 | 0.260 |
Why?
|
| Epirubicin | 8 | 2010 | 82 | 0.260 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 11 | 2011 | 5387 | 0.260 |
Why?
|
| Vinblastine | 12 | 2010 | 482 | 0.260 |
Why?
|
| Colon | 10 | 2009 | 1797 | 0.260 |
Why?
|
| Brain Neoplasms | 20 | 2011 | 9101 | 0.250 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 1960 | 0.250 |
Why?
|
| Lymphoma, Follicular | 1 | 2010 | 460 | 0.250 |
Why?
|
| Job Satisfaction | 2 | 2009 | 548 | 0.250 |
Why?
|
| Rats, Sprague-Dawley | 24 | 2014 | 8106 | 0.250 |
Why?
|
| Follow-Up Studies | 38 | 2021 | 39309 | 0.250 |
Why?
|
| Retrospective Studies | 69 | 2022 | 81635 | 0.240 |
Why?
|
| Cisplatin | 17 | 2009 | 1655 | 0.240 |
Why?
|
| Time Factors | 44 | 2018 | 40149 | 0.240 |
Why?
|
| Mammaplasty | 1 | 2015 | 1268 | 0.240 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 9 | 2008 | 520 | 0.240 |
Why?
|
| Disease-Free Survival | 20 | 2014 | 6850 | 0.230 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 1178 | 0.230 |
Why?
|
| Mitomycin | 11 | 2008 | 261 | 0.230 |
Why?
|
| Dogs | 23 | 2001 | 3834 | 0.230 |
Why?
|
| Tamoxifen | 7 | 2003 | 967 | 0.230 |
Why?
|
| RNA Interference | 9 | 2008 | 2827 | 0.230 |
Why?
|
| Glucose | 7 | 2011 | 4340 | 0.220 |
Why?
|
| Ultrasonography, Interventional | 2 | 2011 | 1520 | 0.220 |
Why?
|
| Health Personnel | 2 | 2016 | 3384 | 0.220 |
Why?
|
| Physician-Patient Relations | 4 | 2015 | 3266 | 0.220 |
Why?
|
| Palliative Care | 11 | 2010 | 3640 | 0.220 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 4056 | 0.220 |
Why?
|
| Risk Assessment | 10 | 2018 | 24295 | 0.220 |
Why?
|
| Glioma | 11 | 2005 | 3498 | 0.220 |
Why?
|
| Neoplasm Staging | 24 | 2018 | 11218 | 0.220 |
Why?
|
| Carcinoma, Ductal, Breast | 6 | 2009 | 1097 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 7431 | 0.220 |
Why?
|
| History, 20th Century | 4 | 2018 | 2764 | 0.220 |
Why?
|
| Needs Assessment | 3 | 2016 | 1140 | 0.220 |
Why?
|
| Tissue Engineering | 7 | 2011 | 1857 | 0.220 |
Why?
|
| Pyloric Antrum | 7 | 1992 | 66 | 0.220 |
Why?
|
| Combined Modality Therapy | 28 | 2009 | 8540 | 0.210 |
Why?
|
| Matrix Metalloproteinase 2 | 5 | 2004 | 461 | 0.210 |
Why?
|
| Intestinal Polyps | 2 | 2003 | 105 | 0.210 |
Why?
|
| Cholecystitis | 3 | 2000 | 181 | 0.210 |
Why?
|
| Intestinal Neoplasms | 4 | 2012 | 314 | 0.210 |
Why?
|
| Analysis of Variance | 17 | 2015 | 6214 | 0.210 |
Why?
|
| Bone Neoplasms | 7 | 2003 | 2561 | 0.200 |
Why?
|
| Quality Improvement | 3 | 2021 | 3850 | 0.200 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2002 | 62 | 0.200 |
Why?
|
| Animals | 109 | 2014 | 168930 | 0.200 |
Why?
|
| Program Development | 2 | 2021 | 1297 | 0.200 |
Why?
|
| Immunocompromised Host | 2 | 2013 | 865 | 0.200 |
Why?
|
| Ischemia | 4 | 2000 | 1905 | 0.200 |
Why?
|
| History, 21st Century | 2 | 2018 | 1574 | 0.200 |
Why?
|
| Healthcare Disparities | 4 | 2022 | 3411 | 0.200 |
Why?
|
| Cell Division | 16 | 2004 | 4474 | 0.190 |
Why?
|
| Carcinoma, Small Cell | 5 | 2006 | 419 | 0.190 |
Why?
|
| RNA, Messenger | 21 | 2014 | 12791 | 0.190 |
Why?
|
| Gastroplasty | 2 | 2012 | 153 | 0.190 |
Why?
|
| Recurrence | 12 | 2020 | 8507 | 0.190 |
Why?
|
| Intussusception | 1 | 2002 | 114 | 0.180 |
Why?
|
| Gastroparesis | 1 | 2003 | 143 | 0.180 |
Why?
|
| Medical Records | 1 | 2006 | 1408 | 0.180 |
Why?
|
| Race Relations | 1 | 2001 | 35 | 0.180 |
Why?
|
| Rats, Inbred Lew | 10 | 2008 | 1168 | 0.180 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 1882 | 0.180 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2001 | 131 | 0.180 |
Why?
|
| Pituitary Neoplasms | 8 | 2006 | 1324 | 0.180 |
Why?
|
| Amiloride | 4 | 1996 | 116 | 0.180 |
Why?
|
| Sodium | 13 | 2002 | 1594 | 0.180 |
Why?
|
| Epidermal Growth Factor | 3 | 2001 | 697 | 0.180 |
Why?
|
| Acute Disease | 18 | 2008 | 7241 | 0.180 |
Why?
|
| src-Family Kinases | 6 | 2004 | 539 | 0.180 |
Why?
|
| Colonic Diseases | 1 | 2002 | 204 | 0.180 |
Why?
|
| Ileostomy | 2 | 1998 | 122 | 0.180 |
Why?
|
| Anthropology, Cultural | 1 | 2001 | 103 | 0.180 |
Why?
|
| Ghrelin | 3 | 2013 | 254 | 0.170 |
Why?
|
| Lipoma | 1 | 2002 | 294 | 0.170 |
Why?
|
| Communication | 4 | 2015 | 3905 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2004 | 2426 | 0.170 |
Why?
|
| Oxygen | 2 | 2011 | 4251 | 0.170 |
Why?
|
| Educational Measurement | 4 | 2024 | 1259 | 0.170 |
Why?
|
| Bariatric Surgery | 1 | 2010 | 996 | 0.170 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 4 | 2001 | 479 | 0.170 |
Why?
|
| Interdisciplinary Communication | 2 | 2016 | 932 | 0.170 |
Why?
|
| Mesentery | 1 | 2000 | 201 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 3 | 2021 | 1061 | 0.160 |
Why?
|
| Gastrointestinal Motility | 2 | 2016 | 235 | 0.160 |
Why?
|
| Caco-2 Cells | 5 | 2013 | 364 | 0.160 |
Why?
|
| Skull Base Neoplasms | 2 | 2002 | 280 | 0.160 |
Why?
|
| Enteritis | 2 | 2000 | 162 | 0.160 |
Why?
|
| England | 5 | 2011 | 533 | 0.160 |
Why?
|
| Physicians | 4 | 2021 | 4591 | 0.160 |
Why?
|
| Observation | 1 | 2001 | 310 | 0.160 |
Why?
|
| Interleukin-10 | 7 | 2007 | 1182 | 0.160 |
Why?
|
| Postoperative Period | 7 | 2015 | 1824 | 0.160 |
Why?
|
| Sexual Harassment | 1 | 2020 | 82 | 0.160 |
Why?
|
| Capsaicin | 2 | 2011 | 233 | 0.160 |
Why?
|
| Stomach Neoplasms | 5 | 2010 | 1474 | 0.160 |
Why?
|
| Severity of Illness Index | 6 | 2016 | 15908 | 0.160 |
Why?
|
| Communication Barriers | 2 | 2015 | 418 | 0.160 |
Why?
|
| Stereotyping | 1 | 2001 | 241 | 0.160 |
Why?
|
| Length of Stay | 12 | 2018 | 6490 | 0.150 |
Why?
|
| Electric Stimulation | 1 | 2003 | 1736 | 0.150 |
Why?
|
| Angioplasty, Balloon | 2 | 2000 | 591 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 12 | 2012 | 3552 | 0.150 |
Why?
|
| Peritoneal Neoplasms | 2 | 2005 | 706 | 0.150 |
Why?
|
| Genes, erbB-2 | 3 | 2011 | 161 | 0.150 |
Why?
|
| Intermittent Claudication | 1 | 2000 | 305 | 0.150 |
Why?
|
| Enterocytes | 4 | 2010 | 220 | 0.150 |
Why?
|
| Career Choice | 4 | 2018 | 768 | 0.150 |
Why?
|
| Analgesia, Epidural | 1 | 2001 | 332 | 0.150 |
Why?
|
| Adenoma | 9 | 2006 | 2155 | 0.150 |
Why?
|
| Genes, BRCA2 | 3 | 2007 | 591 | 0.150 |
Why?
|
| Surgical Wound Infection | 2 | 2018 | 1547 | 0.150 |
Why?
|
| Accreditation | 3 | 2017 | 476 | 0.140 |
Why?
|
| Jejunal Neoplasms | 1 | 1997 | 20 | 0.140 |
Why?
|
| Receptors, Gastrointestinal Hormone | 1 | 1997 | 45 | 0.140 |
Why?
|
| Genes, BRCA1 | 3 | 2007 | 753 | 0.140 |
Why?
|
| Competency-Based Education | 2 | 2010 | 226 | 0.140 |
Why?
|
| Lymphangioma | 1 | 1997 | 60 | 0.140 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 1999 | 371 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 474 | 0.140 |
Why?
|
| RNA, Small Interfering | 9 | 2005 | 3425 | 0.140 |
Why?
|
| Gene Silencing | 5 | 2008 | 1504 | 0.140 |
Why?
|
| Extracellular Space | 3 | 1998 | 563 | 0.140 |
Why?
|
| Popliteal Artery | 2 | 2000 | 312 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2013 | 478 | 0.140 |
Why?
|
| Antibodies | 1 | 2005 | 2421 | 0.140 |
Why?
|
| Regional Blood Flow | 15 | 1999 | 1478 | 0.140 |
Why?
|
| Medical Staff, Hospital | 3 | 2007 | 602 | 0.140 |
Why?
|
| Analgesia | 1 | 2001 | 461 | 0.140 |
Why?
|
| Diagnosis-Related Groups | 1 | 2018 | 445 | 0.140 |
Why?
|
| Proctocolectomy, Restorative | 1 | 1998 | 191 | 0.130 |
Why?
|
| Femoral Artery | 3 | 2000 | 827 | 0.130 |
Why?
|
| Aspirin | 7 | 2004 | 3135 | 0.130 |
Why?
|
| Peptide YY | 9 | 1997 | 135 | 0.130 |
Why?
|
| Body Water | 2 | 1997 | 337 | 0.130 |
Why?
|
| Vagus Nerve | 3 | 2011 | 458 | 0.130 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1997 | 234 | 0.130 |
Why?
|
| Databases, Factual | 5 | 2018 | 8066 | 0.130 |
Why?
|
| Cell Membrane Permeability | 2 | 1999 | 568 | 0.130 |
Why?
|
| Neoplasm Metastasis | 12 | 2018 | 4891 | 0.130 |
Why?
|
| Splenic Diseases | 1 | 1997 | 91 | 0.130 |
Why?
|
| Safety | 3 | 2020 | 1157 | 0.130 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 3 | 2004 | 31 | 0.130 |
Why?
|
| Ireland | 3 | 2007 | 171 | 0.130 |
Why?
|
| Prospective Studies | 21 | 2017 | 54871 | 0.130 |
Why?
|
| Drug Utilization | 2 | 2021 | 1187 | 0.130 |
Why?
|
| Peer Group | 1 | 2022 | 702 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2009 | 633 | 0.130 |
Why?
|
| Judgment | 1 | 2018 | 270 | 0.130 |
Why?
|
| Genetic Testing | 5 | 2010 | 3591 | 0.130 |
Why?
|
| Gene Expression Regulation | 6 | 2012 | 11920 | 0.130 |
Why?
|
| Aortic Rupture | 1 | 1999 | 322 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2022 | 834 | 0.130 |
Why?
|
| Meningioma | 3 | 2002 | 1221 | 0.130 |
Why?
|
| Faculty, Medical | 4 | 2012 | 1226 | 0.130 |
Why?
|
| GPI-Linked Proteins | 10 | 2005 | 472 | 0.130 |
Why?
|
| Chi-Square Distribution | 5 | 2011 | 3432 | 0.130 |
Why?
|
| Fundoplication | 2 | 2007 | 146 | 0.120 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 2534 | 0.120 |
Why?
|
| Peptide Biosynthesis | 1 | 1995 | 52 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 13 | 1999 | 2478 | 0.120 |
Why?
|
| Morbidity | 4 | 2020 | 1754 | 0.120 |
Why?
|
| Water | 6 | 1999 | 1417 | 0.120 |
Why?
|
| Crohn Disease | 3 | 2013 | 2286 | 0.120 |
Why?
|
| Cyclophosphamide | 10 | 2009 | 2234 | 0.120 |
Why?
|
| Patient Simulation | 1 | 2017 | 300 | 0.120 |
Why?
|
| G1 Phase | 2 | 2013 | 403 | 0.120 |
Why?
|
| Hemophilia B | 1 | 2015 | 83 | 0.120 |
Why?
|
| Sodium Channel Blockers | 1 | 1996 | 171 | 0.120 |
Why?
|
| Hospital Administration | 1 | 2018 | 351 | 0.120 |
Why?
|
| Cats | 10 | 1999 | 972 | 0.120 |
Why?
|
| Angioplasty, Balloon, Laser-Assisted | 1 | 1994 | 20 | 0.120 |
Why?
|
| Clinical Clerkship | 2 | 2011 | 569 | 0.120 |
Why?
|
| Membrane Potentials | 7 | 1989 | 1085 | 0.120 |
Why?
|
| Gallbladder | 1 | 1996 | 308 | 0.120 |
Why?
|
| Vagotomy | 2 | 2011 | 82 | 0.120 |
Why?
|
| Pancreatic Diseases | 3 | 2008 | 353 | 0.120 |
Why?
|
| United States | 19 | 2022 | 72951 | 0.120 |
Why?
|
| Cholelithiasis | 4 | 2003 | 408 | 0.120 |
Why?
|
| Efficiency | 2 | 2015 | 479 | 0.120 |
Why?
|
| Chlorides | 7 | 2002 | 666 | 0.120 |
Why?
|
| Boston | 5 | 2020 | 9346 | 0.120 |
Why?
|
| Mitoxantrone | 6 | 2003 | 148 | 0.120 |
Why?
|
| Receptor, EphA2 | 2 | 2004 | 41 | 0.110 |
Why?
|
| Signal Transduction | 7 | 2009 | 23619 | 0.110 |
Why?
|
| Quinazolines | 2 | 2011 | 1367 | 0.110 |
Why?
|
| Guideline Adherence | 4 | 2021 | 2234 | 0.110 |
Why?
|
| Hydrogen | 7 | 2000 | 168 | 0.110 |
Why?
|
| Hematologic Neoplasms | 2 | 2008 | 1926 | 0.110 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2006 | 1251 | 0.110 |
Why?
|
| Forecasting | 2 | 2018 | 2936 | 0.110 |
Why?
|
| Esophagogastric Junction | 2 | 2007 | 350 | 0.110 |
Why?
|
| Anoikis | 2 | 2004 | 49 | 0.110 |
Why?
|
| Endotoxins | 1 | 1996 | 519 | 0.110 |
Why?
|
| Lymphoma | 3 | 2001 | 1900 | 0.110 |
Why?
|
| Short Bowel Syndrome | 2 | 2012 | 352 | 0.110 |
Why?
|
| Language Disorders | 1 | 1995 | 140 | 0.110 |
Why?
|
| Speech Disorders | 1 | 1995 | 178 | 0.110 |
Why?
|
| Drug Administration Schedule | 10 | 2010 | 4853 | 0.110 |
Why?
|
| Blotting, Western | 10 | 2012 | 5022 | 0.110 |
Why?
|
| Workplace | 1 | 2020 | 873 | 0.110 |
Why?
|
| Stomach | 2 | 1996 | 701 | 0.110 |
Why?
|
| Physician Assistants | 1 | 2015 | 190 | 0.110 |
Why?
|
| Premenopause | 2 | 2004 | 1039 | 0.110 |
Why?
|
| History, 19th Century | 3 | 2008 | 714 | 0.110 |
Why?
|
| Incidence | 8 | 2016 | 21525 | 0.110 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2021 | 996 | 0.100 |
Why?
|
| Pain, Postoperative | 3 | 2001 | 1768 | 0.100 |
Why?
|
| Diagnosis, Differential | 6 | 2014 | 12985 | 0.100 |
Why?
|
| Stroke | 2 | 2014 | 9741 | 0.100 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 1997 | 372 | 0.100 |
Why?
|
| Hemostatics | 1 | 2015 | 247 | 0.100 |
Why?
|
| Arterial Occlusive Diseases | 2 | 1994 | 742 | 0.100 |
Why?
|
| E-Box Elements | 1 | 2012 | 21 | 0.100 |
Why?
|
| S Phase | 1 | 2013 | 424 | 0.100 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2013 | 79 | 0.100 |
Why?
|
| Receptors, Estrogen | 4 | 2011 | 2251 | 0.100 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1996 | 399 | 0.100 |
Why?
|
| Burnout, Professional | 1 | 2021 | 710 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2013 | 2456 | 0.100 |
Why?
|
| Chronobiology Disorders | 1 | 2013 | 73 | 0.100 |
Why?
|
| Obesity | 4 | 2013 | 13090 | 0.100 |
Why?
|
| Multivariate Analysis | 14 | 2014 | 12064 | 0.100 |
Why?
|
| Research | 1 | 2001 | 1977 | 0.100 |
Why?
|
| Decision Making | 5 | 2011 | 3951 | 0.100 |
Why?
|
| Biological Transport | 3 | 2010 | 2083 | 0.100 |
Why?
|
| Carcinoma, Lobular | 2 | 2009 | 480 | 0.100 |
Why?
|
| Hemophilia A | 1 | 2015 | 359 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 4 | 2021 | 7475 | 0.100 |
Why?
|
| Hematoma | 1 | 1997 | 766 | 0.100 |
Why?
|
| Boidae | 2 | 2002 | 14 | 0.100 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 1991 | 44 | 0.100 |
Why?
|
| Apoptosis | 12 | 2012 | 9513 | 0.100 |
Why?
|
| Colectomy | 3 | 2006 | 696 | 0.100 |
Why?
|
| Period Circadian Proteins | 1 | 2012 | 97 | 0.100 |
Why?
|
| Genetic Counseling | 2 | 2010 | 634 | 0.100 |
Why?
|
| Vincristine | 6 | 1999 | 1039 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 1663 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 5690 | 0.090 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2012 | 100 | 0.090 |
Why?
|
| Caspases | 8 | 2006 | 881 | 0.090 |
Why?
|
| Alanine Transaminase | 2 | 2012 | 608 | 0.090 |
Why?
|
| Risk Factors | 18 | 2020 | 74881 | 0.090 |
Why?
|
| Esophageal Neoplasms | 3 | 2010 | 1660 | 0.090 |
Why?
|
| Soft Tissue Infections | 1 | 2013 | 166 | 0.090 |
Why?
|
| Preoperative Care | 3 | 2015 | 2253 | 0.090 |
Why?
|
| Specialization | 1 | 2016 | 779 | 0.090 |
Why?
|
| Radiotherapy, Conformal | 2 | 2006 | 545 | 0.090 |
Why?
|
| Dacarbazine | 2 | 2005 | 552 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2001 | 1941 | 0.090 |
Why?
|
| Glucose Transporter Type 2 | 3 | 2005 | 61 | 0.090 |
Why?
|
| Chronic Disease | 11 | 2014 | 9357 | 0.090 |
Why?
|
| Plagiarism | 1 | 2010 | 22 | 0.090 |
Why?
|
| Cholecystokinin | 3 | 1996 | 114 | 0.090 |
Why?
|
| Intestinal Diseases | 2 | 2010 | 506 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 1999 | 1161 | 0.090 |
Why?
|
| Afferent Pathways | 1 | 2011 | 303 | 0.090 |
Why?
|
| Thrombophlebitis | 1 | 2011 | 289 | 0.090 |
Why?
|
| Ethanol | 5 | 1998 | 1326 | 0.090 |
Why?
|
| Estrogen Antagonists | 2 | 2003 | 151 | 0.090 |
Why?
|
| Strongyloides stercoralis | 1 | 2010 | 23 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 198 | 0.090 |
Why?
|
| Data Collection | 3 | 2011 | 3321 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2013 | 2881 | 0.090 |
Why?
|
| Curriculum | 2 | 2018 | 3783 | 0.090 |
Why?
|
| Pleural Neoplasms | 2 | 2005 | 584 | 0.090 |
Why?
|
| Lymphatic Metastasis | 6 | 2018 | 2901 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2006 | 1536 | 0.090 |
Why?
|
| Veterans Health | 2 | 2022 | 216 | 0.090 |
Why?
|
| Bioengineering | 1 | 2011 | 97 | 0.090 |
Why?
|
| Young Adult | 9 | 2018 | 59939 | 0.090 |
Why?
|
| Patient Selection | 3 | 2009 | 4252 | 0.080 |
Why?
|
| Centralized Hospital Services | 1 | 2009 | 15 | 0.080 |
Why?
|
| Methotrexate | 9 | 2003 | 1719 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2021 | 1880 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2005 | 614 | 0.080 |
Why?
|
| Drug Chronotherapy | 1 | 2009 | 10 | 0.080 |
Why?
|
| Lymph Node Excision | 3 | 2006 | 1267 | 0.080 |
Why?
|
| Ultrasonography | 5 | 2014 | 5992 | 0.080 |
Why?
|
| Bacterial Infections | 2 | 2009 | 1390 | 0.080 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2009 | 17 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2014 | 1245 | 0.080 |
Why?
|
| Doxorubicin | 7 | 2009 | 2229 | 0.080 |
Why?
|
| Hyperpigmentation | 1 | 2011 | 116 | 0.080 |
Why?
|
| Mastectomy | 3 | 2015 | 1861 | 0.080 |
Why?
|
| Food | 5 | 2010 | 764 | 0.080 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 1749 | 0.080 |
Why?
|
| Anastomosis, Surgical | 3 | 2005 | 992 | 0.080 |
Why?
|
| Carboplatin | 5 | 2008 | 789 | 0.080 |
Why?
|
| Electric Conductivity | 8 | 2001 | 405 | 0.080 |
Why?
|
| Cell Line, Tumor | 18 | 2006 | 17088 | 0.080 |
Why?
|
| Gastric Acidity Determination | 1 | 1989 | 56 | 0.080 |
Why?
|
| Mice, Nude | 9 | 2004 | 3616 | 0.080 |
Why?
|
| Isoenzymes | 4 | 2004 | 1688 | 0.080 |
Why?
|
| Postmenopause | 3 | 2004 | 2517 | 0.080 |
Why?
|
| Neoplasms | 5 | 2010 | 22350 | 0.080 |
Why?
|
| Infusions, Intravenous | 6 | 2007 | 2228 | 0.080 |
Why?
|
| Skin Pigmentation | 1 | 2011 | 278 | 0.080 |
Why?
|
| Informed Consent | 1 | 2015 | 1010 | 0.080 |
Why?
|
| Glucose Intolerance | 1 | 2013 | 578 | 0.080 |
Why?
|
| Skin | 1 | 2002 | 4499 | 0.080 |
Why?
|
| Tomography, Emission-Computed | 1 | 2011 | 1006 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 2 | 2008 | 1368 | 0.080 |
Why?
|
| Immunohistochemistry | 7 | 2008 | 11061 | 0.080 |
Why?
|
| Antineoplastic Agents | 9 | 2012 | 13643 | 0.080 |
Why?
|
| Glucose Transporter Type 5 | 2 | 2005 | 13 | 0.080 |
Why?
|
| Hospitals, Teaching | 3 | 2012 | 1156 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 2 | 2013 | 1491 | 0.080 |
Why?
|
| Receptors, Progesterone | 2 | 2011 | 1159 | 0.080 |
Why?
|
| Stomach Ulcer | 2 | 1987 | 118 | 0.080 |
Why?
|
| Microelectrodes | 6 | 1994 | 305 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 949 | 0.080 |
Why?
|
| Necturus | 6 | 1987 | 14 | 0.080 |
Why?
|
| Random Allocation | 3 | 2005 | 2394 | 0.080 |
Why?
|
| Epithelial Cells | 3 | 2013 | 3691 | 0.080 |
Why?
|
| Cerebral Angiography | 1 | 2014 | 1263 | 0.080 |
Why?
|
| Radiotherapy Dosage | 10 | 2006 | 2911 | 0.080 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2010 | 357 | 0.070 |
Why?
|
| Splenic Neoplasms | 1 | 2008 | 97 | 0.070 |
Why?
|
| Veterans | 1 | 2022 | 2667 | 0.070 |
Why?
|
| Thrombocytopenia | 2 | 2015 | 1172 | 0.070 |
Why?
|
| Feasibility Studies | 9 | 2016 | 5306 | 0.070 |
Why?
|
| Sarcoma | 3 | 2010 | 1802 | 0.070 |
Why?
|
| Adolescent | 37 | 2017 | 88904 | 0.070 |
Why?
|
| Biopsy, Needle | 4 | 2005 | 1615 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 9 | 2004 | 6104 | 0.070 |
Why?
|
| Endothelins | 2 | 1998 | 127 | 0.070 |
Why?
|
| Transcription, Genetic | 5 | 2008 | 7609 | 0.070 |
Why?
|
| Academic Medical Centers | 4 | 2016 | 2783 | 0.070 |
Why?
|
| Physician Incentive Plans | 1 | 2009 | 165 | 0.070 |
Why?
|
| Splenectomy | 2 | 2002 | 390 | 0.070 |
Why?
|
| Keratins | 2 | 2006 | 499 | 0.070 |
Why?
|
| Colitis, Ulcerative | 2 | 1998 | 1920 | 0.070 |
Why?
|
| Biological Clocks | 1 | 2010 | 320 | 0.070 |
Why?
|
| Thienamycins | 1 | 2007 | 29 | 0.070 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2009 | 329 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2009 | 365 | 0.070 |
Why?
|
| Receptors, Glucagon | 2 | 2004 | 90 | 0.070 |
Why?
|
| Portal Vein | 1 | 1990 | 437 | 0.070 |
Why?
|
| Acetates | 1 | 1989 | 314 | 0.070 |
Why?
|
| Transfection | 7 | 2012 | 5754 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2013 | 10745 | 0.070 |
Why?
|
| HMGA Proteins | 1 | 2006 | 7 | 0.070 |
Why?
|
| Focal Adhesion Kinase 1 | 5 | 2004 | 120 | 0.070 |
Why?
|
| World Health Organization | 2 | 2011 | 1327 | 0.070 |
Why?
|
| Eating | 7 | 2008 | 1539 | 0.070 |
Why?
|
| Sensory Receptor Cells | 1 | 2011 | 509 | 0.070 |
Why?
|
| Muscle, Smooth | 2 | 2010 | 931 | 0.070 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 5 | 2004 | 183 | 0.070 |
Why?
|
| Liver Neoplasms | 4 | 2010 | 4353 | 0.070 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2006 | 25 | 0.070 |
Why?
|
| Antigens, CD | 10 | 2005 | 4032 | 0.070 |
Why?
|
| Respirovirus Infections | 1 | 2006 | 51 | 0.070 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 319 | 0.070 |
Why?
|
| Bone Density | 2 | 1998 | 3491 | 0.070 |
Why?
|
| Medical Errors | 2 | 2011 | 1260 | 0.070 |
Why?
|
| Catheterization, Peripheral | 1 | 1990 | 346 | 0.070 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 2006 | 31 | 0.070 |
Why?
|
| Video Recording | 1 | 2012 | 976 | 0.070 |
Why?
|
| Chewing Gum | 1 | 2006 | 40 | 0.070 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2006 | 56 | 0.070 |
Why?
|
| Surgical Flaps | 1 | 2015 | 1680 | 0.070 |
Why?
|
| Risk Management | 2 | 2007 | 558 | 0.060 |
Why?
|
| Platelet Activating Factor | 2 | 2001 | 142 | 0.060 |
Why?
|
| Sucrase | 3 | 2005 | 51 | 0.060 |
Why?
|
| DNA | 5 | 2010 | 7208 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 1995 | 2141 | 0.060 |
Why?
|
| Transplantation, Isogeneic | 2 | 2004 | 250 | 0.060 |
Why?
|
| Ileus | 1 | 2006 | 65 | 0.060 |
Why?
|
| Language | 1 | 2015 | 1550 | 0.060 |
Why?
|
| Carbapenems | 1 | 2007 | 125 | 0.060 |
Why?
|
| Ependymoma | 1 | 2009 | 326 | 0.060 |
Why?
|
| Prostaglandins E, Synthetic | 1 | 1985 | 14 | 0.060 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2006 | 55 | 0.060 |
Why?
|
| Neoplasm Transplantation | 6 | 2004 | 2012 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 2078 | 0.060 |
Why?
|
| Hoarseness | 1 | 2006 | 63 | 0.060 |
Why?
|
| Vascular Patency | 2 | 2000 | 915 | 0.060 |
Why?
|
| Ion Transport | 2 | 1997 | 322 | 0.060 |
Why?
|
| 16,16-Dimethylprostaglandin E2 | 1 | 1985 | 22 | 0.060 |
Why?
|
| Enterostomy | 1 | 2005 | 14 | 0.060 |
Why?
|
| Colorectal Surgery | 1 | 2007 | 125 | 0.060 |
Why?
|
| Leadership | 2 | 2012 | 1394 | 0.060 |
Why?
|
| Fellowships and Scholarships | 2 | 2011 | 1134 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 2 | 2001 | 358 | 0.060 |
Why?
|
| Sensitivity and Specificity | 6 | 2012 | 14652 | 0.060 |
Why?
|
| RNA Transport | 1 | 2005 | 42 | 0.060 |
Why?
|
| Neutropenia | 2 | 2009 | 894 | 0.060 |
Why?
|
| Pilot Projects | 9 | 2016 | 8728 | 0.060 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2008 | 393 | 0.060 |
Why?
|
| Cecum | 4 | 2001 | 231 | 0.060 |
Why?
|
| MicroRNAs | 2 | 2012 | 3792 | 0.060 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 167 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 1394 | 0.060 |
Why?
|
| Hospital Mortality | 3 | 2014 | 5343 | 0.060 |
Why?
|
| Attention | 1 | 2015 | 2413 | 0.060 |
Why?
|
| Dideoxyadenosine | 1 | 2004 | 9 | 0.060 |
Why?
|
| Pancreatic Function Tests | 1 | 2005 | 69 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 3511 | 0.060 |
Why?
|
| Administration, Oral | 5 | 1999 | 4018 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 3 | 2012 | 5789 | 0.060 |
Why?
|
| Duodenal Neoplasms | 2 | 2003 | 114 | 0.060 |
Why?
|
| Cardia | 1 | 2004 | 61 | 0.060 |
Why?
|
| Dinoprostone | 2 | 2004 | 597 | 0.060 |
Why?
|
| Logistic Models | 3 | 2016 | 13278 | 0.060 |
Why?
|
| Hospital Charges | 2 | 2011 | 345 | 0.060 |
Why?
|
| Suicide | 1 | 2016 | 1606 | 0.060 |
Why?
|
| Secretin | 2 | 1995 | 57 | 0.060 |
Why?
|
| Pertussis Toxin | 1 | 2004 | 176 | 0.060 |
Why?
|
| Fractures, Bone | 1 | 1996 | 2043 | 0.060 |
Why?
|
| Bicarbonates | 3 | 1994 | 293 | 0.060 |
Why?
|
| Mammography | 3 | 2009 | 2429 | 0.060 |
Why?
|
| Disease Progression | 10 | 2011 | 13640 | 0.060 |
Why?
|
| Suture Techniques | 2 | 2007 | 775 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2011 | 1171 | 0.060 |
Why?
|
| Teaching | 1 | 2012 | 1171 | 0.060 |
Why?
|
| Diagnostic Techniques, Respiratory System | 1 | 2003 | 13 | 0.060 |
Why?
|
| Program Evaluation | 3 | 2018 | 2504 | 0.060 |
Why?
|
| Minority Groups | 2 | 2022 | 1208 | 0.060 |
Why?
|
| Checklist | 1 | 2011 | 841 | 0.060 |
Why?
|
| Unnecessary Procedures | 1 | 2007 | 412 | 0.060 |
Why?
|
| Methods | 3 | 1994 | 1065 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2020 | 13050 | 0.060 |
Why?
|
| Biliary Tract Diseases | 1 | 1985 | 159 | 0.060 |
Why?
|
| Myosin Type II | 1 | 2004 | 71 | 0.060 |
Why?
|
| Esophagoscopy | 1 | 2006 | 398 | 0.060 |
Why?
|
| Appendectomy | 1 | 2007 | 445 | 0.060 |
Why?
|
| Ki-67 Antigen | 3 | 2004 | 630 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 1804 | 0.060 |
Why?
|
| Caveolins | 1 | 2004 | 102 | 0.060 |
Why?
|
| Rats, Zucker | 2 | 2014 | 130 | 0.060 |
Why?
|
| Gastric Acid | 4 | 1988 | 98 | 0.060 |
Why?
|
| Mycoses | 1 | 2007 | 389 | 0.060 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2004 | 102 | 0.050 |
Why?
|
| Fibronectins | 2 | 2004 | 722 | 0.050 |
Why?
|
| Phlorhizin | 4 | 2008 | 37 | 0.050 |
Why?
|
| Carcinoma | 2 | 2010 | 2324 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2008 | 619 | 0.050 |
Why?
|
| Pregnancy Complications | 2 | 2007 | 2971 | 0.050 |
Why?
|
| Comprehension | 1 | 2009 | 638 | 0.050 |
Why?
|
| Telemedicine | 1 | 2021 | 3111 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 20144 | 0.050 |
Why?
|
| Appendicitis | 2 | 2007 | 680 | 0.050 |
Why?
|
| Vindesine | 2 | 1998 | 12 | 0.050 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 2188 | 0.050 |
Why?
|
| Physicians, Women | 1 | 2009 | 516 | 0.050 |
Why?
|
| Hemangioma | 1 | 2008 | 727 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2016 | 3465 | 0.050 |
Why?
|
| Nutritional Support | 1 | 2005 | 178 | 0.050 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2003 | 147 | 0.050 |
Why?
|
| Splenic Vein | 1 | 2002 | 30 | 0.050 |
Why?
|
| Disease Models, Animal | 8 | 2011 | 18330 | 0.050 |
Why?
|
| Double-Blind Method | 8 | 2007 | 12430 | 0.050 |
Why?
|
| Light | 2 | 2010 | 1358 | 0.050 |
Why?
|
| Inservice Training | 2 | 2018 | 374 | 0.050 |
Why?
|
| Enteral Nutrition | 3 | 2013 | 802 | 0.050 |
Why?
|
| Growth Hormone | 2 | 2006 | 572 | 0.050 |
Why?
|
| Affective Symptoms | 1 | 2006 | 418 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2011 | 2028 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2007 | 18075 | 0.050 |
Why?
|
| Lymphangiogenesis | 1 | 2004 | 171 | 0.050 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2002 | 54 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2006 | 540 | 0.050 |
Why?
|
| Fat Necrosis | 1 | 2002 | 60 | 0.050 |
Why?
|
| Injections, Intravenous | 3 | 2000 | 1377 | 0.050 |
Why?
|
| Necturus maculosus | 3 | 1989 | 5 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 1995 | 1374 | 0.050 |
Why?
|
| Peptide Hormones | 1 | 2003 | 133 | 0.050 |
Why?
|
| Blood Loss, Surgical | 2 | 2011 | 642 | 0.050 |
Why?
|
| Amylases | 5 | 2001 | 171 | 0.050 |
Why?
|
| Students, Medical | 2 | 2013 | 1962 | 0.050 |
Why?
|
| Microcirculation | 3 | 1996 | 1282 | 0.050 |
Why?
|
| Digestive System Diseases | 1 | 1984 | 152 | 0.050 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2009 | 1226 | 0.050 |
Why?
|
| Craniopharyngioma | 2 | 1997 | 279 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 3837 | 0.050 |
Why?
|
| Remission Induction | 5 | 2013 | 2413 | 0.050 |
Why?
|
| Thyroid Neoplasms | 2 | 2010 | 2355 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2005 | 4522 | 0.050 |
Why?
|
| Cholera Toxin | 1 | 2004 | 562 | 0.050 |
Why?
|
| Appendiceal Neoplasms | 1 | 2004 | 155 | 0.050 |
Why?
|
| Cough | 1 | 2006 | 599 | 0.050 |
Why?
|
| Mother-Child Relations | 1 | 2006 | 498 | 0.050 |
Why?
|
| Blotting, Northern | 4 | 2005 | 1550 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2013 | 12245 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 2 | 2007 | 834 | 0.050 |
Why?
|
| Reference Values | 4 | 2011 | 4913 | 0.050 |
Why?
|
| Transforming Growth Factors | 1 | 2001 | 76 | 0.050 |
Why?
|
| Neutrophil Activation | 2 | 2001 | 180 | 0.050 |
Why?
|
| Mitomycins | 5 | 2005 | 45 | 0.050 |
Why?
|
| Nervous System Diseases | 2 | 2011 | 1659 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 591 | 0.050 |
Why?
|
| Cell Membrane | 5 | 2005 | 3641 | 0.050 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 1292 | 0.050 |
Why?
|
| Amputation Stumps | 1 | 2001 | 38 | 0.050 |
Why?
|
| Intestinal Fistula | 2 | 2000 | 146 | 0.050 |
Why?
|
| Radiography, Interventional | 1 | 2009 | 1129 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 2 | 1998 | 945 | 0.050 |
Why?
|
| Endarterectomy, Carotid | 1 | 2006 | 556 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 1 | 2004 | 358 | 0.050 |
Why?
|
| Literature | 1 | 2001 | 15 | 0.050 |
Why?
|
| Prednisone | 3 | 2007 | 1566 | 0.050 |
Why?
|
| Potassium | 5 | 2002 | 1314 | 0.050 |
Why?
|
| Gene Targeting | 1 | 2004 | 840 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 1990 | 1183 | 0.050 |
Why?
|
| Sepsis | 3 | 2001 | 2604 | 0.050 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2009 | 996 | 0.050 |
Why?
|
| Parent-Child Relations | 1 | 2006 | 772 | 0.050 |
Why?
|
| Child Behavior Disorders | 1 | 2006 | 812 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 462 | 0.050 |
Why?
|
| Interprofessional Relations | 2 | 2021 | 998 | 0.040 |
Why?
|
| Administration, Rectal | 1 | 2000 | 69 | 0.040 |
Why?
|
| Piperacillin | 1 | 2000 | 37 | 0.040 |
Why?
|
| Drainage | 2 | 2009 | 1182 | 0.040 |
Why?
|
| Microspheres | 5 | 1987 | 774 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2014 | 3799 | 0.040 |
Why?
|
| Radiography | 5 | 2009 | 6968 | 0.040 |
Why?
|
| Stereotyped Behavior | 1 | 2001 | 133 | 0.040 |
Why?
|
| Lipase | 1 | 2002 | 320 | 0.040 |
Why?
|
| Platinum Compounds | 2 | 2011 | 94 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 889 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2003 | 392 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2004 | 1472 | 0.040 |
Why?
|
| Up-Regulation | 4 | 2012 | 4142 | 0.040 |
Why?
|
| Stem Cell Transplantation | 2 | 2006 | 1600 | 0.040 |
Why?
|
| Weight Loss | 3 | 2012 | 2712 | 0.040 |
Why?
|
| Parenteral Nutrition | 1 | 2005 | 661 | 0.040 |
Why?
|
| Membrane Proteins | 4 | 2005 | 7868 | 0.040 |
Why?
|
| Cohort Studies | 14 | 2013 | 41710 | 0.040 |
Why?
|
| Mastectomy, Segmental | 3 | 2006 | 974 | 0.040 |
Why?
|
| Minority Health | 1 | 2001 | 79 | 0.040 |
Why?
|
| Indomethacin | 1 | 2000 | 323 | 0.040 |
Why?
|
| Pancreaticojejunostomy | 1 | 1999 | 26 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 36567 | 0.040 |
Why?
|
| Leucine | 1 | 2001 | 547 | 0.040 |
Why?
|
| Radiodermatitis | 1 | 2000 | 61 | 0.040 |
Why?
|
| Reperfusion Injury | 2 | 1997 | 1043 | 0.040 |
Why?
|
| Epithelium | 5 | 1992 | 1606 | 0.040 |
Why?
|
| Skin Care | 1 | 2000 | 54 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 2002 | 400 | 0.040 |
Why?
|
| Ligation | 2 | 2000 | 446 | 0.040 |
Why?
|
| Phantom Limb | 1 | 2001 | 106 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 1029 | 0.040 |
Why?
|
| Hair Diseases | 1 | 2000 | 72 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2021 | 174 | 0.040 |
Why?
|
| Mexico | 1 | 2022 | 770 | 0.040 |
Why?
|
| Cytokines | 3 | 2007 | 7438 | 0.040 |
Why?
|
| Antibodies, Neoplasm | 1 | 2000 | 282 | 0.040 |
Why?
|
| Carcinoma in Situ | 1 | 2005 | 784 | 0.040 |
Why?
|
| Gene Expression Profiling | 3 | 2006 | 9525 | 0.040 |
Why?
|
| Decision Trees | 1 | 2001 | 508 | 0.040 |
Why?
|
| Absorption | 1 | 1999 | 242 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2007 | 1404 | 0.040 |
Why?
|
| Maltose | 1 | 1999 | 39 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2004 | 678 | 0.040 |
Why?
|
| Chest Pain | 1 | 2006 | 1101 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 6512 | 0.040 |
Why?
|
| Nursing Staff | 1 | 2000 | 113 | 0.040 |
Why?
|
| Phosphorylation | 5 | 2013 | 8307 | 0.040 |
Why?
|
| Meningeal Neoplasms | 2 | 2002 | 1255 | 0.040 |
Why?
|
| Enzyme Inhibitors | 3 | 2003 | 3721 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2006 | 5329 | 0.040 |
Why?
|
| Jaundice, Obstructive | 1 | 2018 | 22 | 0.040 |
Why?
|
| Tomography | 1 | 2001 | 443 | 0.040 |
Why?
|
| Mannitol | 1 | 1999 | 176 | 0.040 |
Why?
|
| Neoplasm, Residual | 4 | 2006 | 1012 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2007 | 4349 | 0.040 |
Why?
|
| Norethindrone | 1 | 1998 | 52 | 0.040 |
Why?
|
| Abdominal Abscess | 1 | 2000 | 152 | 0.040 |
Why?
|
| Malabsorption Syndromes | 2 | 1996 | 135 | 0.040 |
Why?
|
| Tunica Intima | 1 | 2000 | 455 | 0.040 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2005 | 882 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2012 | 3796 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 2 | 2001 | 2730 | 0.040 |
Why?
|
| Predictive Value of Tests | 6 | 2011 | 15416 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2015 | 26310 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2016 | 22248 | 0.040 |
Why?
|
| Common Bile Duct | 2 | 2011 | 106 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2022 | 7841 | 0.040 |
Why?
|
| Stem Cells | 1 | 2011 | 3537 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 3 | 2012 | 1622 | 0.040 |
Why?
|
| Astrocytoma | 2 | 1993 | 773 | 0.040 |
Why?
|
| Faculty | 1 | 2021 | 383 | 0.040 |
Why?
|
| Base Sequence | 4 | 2003 | 12415 | 0.040 |
Why?
|
| Blood Flow Velocity | 2 | 2000 | 1374 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2001 | 738 | 0.040 |
Why?
|
| Interleukin-1 | 2 | 2001 | 1251 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2004 | 8621 | 0.040 |
Why?
|
| Tibial Arteries | 1 | 1997 | 60 | 0.040 |
Why?
|
| Actuarial Analysis | 4 | 1999 | 370 | 0.040 |
Why?
|
| Placebos | 2 | 2006 | 1659 | 0.040 |
Why?
|
| Protozoan Proteins | 1 | 2003 | 843 | 0.040 |
Why?
|
| Penicillins | 1 | 2000 | 404 | 0.030 |
Why?
|
| Leukemia, Myeloid | 1 | 2000 | 695 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2002 | 802 | 0.030 |
Why?
|
| Age Factors | 9 | 2011 | 18397 | 0.030 |
Why?
|
| Mucins | 1 | 2000 | 569 | 0.030 |
Why?
|
| Cross Infection | 1 | 2006 | 1427 | 0.030 |
Why?
|
| Hemorrhage | 2 | 2001 | 3464 | 0.030 |
Why?
|
| Bleomycin | 1 | 1998 | 492 | 0.030 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 12534 | 0.030 |
Why?
|
| Femoral Vein | 1 | 1997 | 156 | 0.030 |
Why?
|
| Scalp | 1 | 2000 | 390 | 0.030 |
Why?
|
| Carbohydrates | 1 | 1999 | 387 | 0.030 |
Why?
|
| Quality of Life | 11 | 2005 | 13476 | 0.030 |
Why?
|
| Emotional Intelligence | 1 | 2018 | 135 | 0.030 |
Why?
|
| Vasopressins | 4 | 1987 | 358 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 1997 | 2429 | 0.030 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1997 | 179 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 5536 | 0.030 |
Why?
|
| Sex Factors | 3 | 2021 | 10619 | 0.030 |
Why?
|
| Cricetinae | 2 | 2012 | 2416 | 0.030 |
Why?
|
| Heterozygote | 3 | 2007 | 2795 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 1998 | 251 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2003 | 1275 | 0.030 |
Why?
|
| Prejudice | 1 | 2001 | 568 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 1935 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2000 | 587 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 6307 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 4 | 2003 | 6066 | 0.030 |
Why?
|
| Burns | 1 | 2008 | 1902 | 0.030 |
Why?
|
| Lymphedema | 1 | 2003 | 526 | 0.030 |
Why?
|
| Information Systems | 1 | 2018 | 400 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 1730 | 0.030 |
Why?
|
| Catheter Ablation | 1 | 2010 | 2786 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 1646 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2010 | 4049 | 0.030 |
Why?
|
| Liver Diseases | 1 | 1985 | 1303 | 0.030 |
Why?
|
| Hair | 1 | 2000 | 508 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 9244 | 0.030 |
Why?
|
| Macrophages | 3 | 2007 | 5783 | 0.030 |
Why?
|
| Robotics | 1 | 2003 | 807 | 0.030 |
Why?
|
| Kinetics | 3 | 2001 | 6287 | 0.030 |
Why?
|
| Referral and Consultation | 2 | 2006 | 3618 | 0.030 |
Why?
|
| Leucovorin | 1 | 1998 | 644 | 0.030 |
Why?
|
| Axilla | 3 | 2006 | 622 | 0.030 |
Why?
|
| Mice | 17 | 2007 | 81889 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 3079 | 0.030 |
Why?
|
| Graft Survival | 2 | 2003 | 3904 | 0.030 |
Why?
|
| Pyrimidines | 4 | 2012 | 3043 | 0.030 |
Why?
|
| Burkitt Lymphoma | 1 | 1998 | 338 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2017 | 252 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2008 | 5753 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 2002 | 1479 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 3738 | 0.030 |
Why?
|
| Insurance Selection Bias | 2 | 2007 | 69 | 0.030 |
Why?
|
| Microvilli | 3 | 2002 | 234 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2011 | 6550 | 0.030 |
Why?
|
| Endometrium | 1 | 1998 | 406 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2002 | 1155 | 0.030 |
Why?
|
| Kidney | 1 | 2011 | 7074 | 0.030 |
Why?
|
| Lymphoma, T-Cell | 1 | 1998 | 308 | 0.030 |
Why?
|
| omega-N-Methylarginine | 1 | 1995 | 108 | 0.030 |
Why?
|
| Imidazoles | 1 | 2001 | 1168 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2008 | 4924 | 0.030 |
Why?
|
| Colonoscopy | 2 | 2002 | 1409 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 1244 | 0.030 |
Why?
|
| Calcium | 3 | 1993 | 5783 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2001 | 913 | 0.030 |
Why?
|
| APACHE | 1 | 1995 | 268 | 0.030 |
Why?
|
| Software | 1 | 2009 | 4466 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2003 | 3607 | 0.030 |
Why?
|
| Nitroprusside | 1 | 1995 | 271 | 0.030 |
Why?
|
| Saccharin | 1 | 2014 | 20 | 0.030 |
Why?
|
| Age of Onset | 2 | 2004 | 3342 | 0.030 |
Why?
|
| Multilingualism | 1 | 2015 | 88 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2009 | 3236 | 0.030 |
Why?
|
| Hydrochloric Acid | 2 | 2002 | 76 | 0.030 |
Why?
|
| Quality of Health Care | 3 | 2009 | 4306 | 0.030 |
Why?
|
| Body Weight | 3 | 2011 | 4626 | 0.030 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1995 | 149 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2003 | 2448 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2003 | 2115 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2004 | 2270 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 511 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2008 | 4570 | 0.030 |
Why?
|
| Necrosis | 2 | 1996 | 1616 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1995 | 774 | 0.030 |
Why?
|
| Health Facility Size | 1 | 2014 | 59 | 0.030 |
Why?
|
| Permeability | 1 | 1996 | 721 | 0.030 |
Why?
|
| Survival | 1 | 1995 | 160 | 0.030 |
Why?
|
| Organoplatinum Compounds | 2 | 2010 | 406 | 0.030 |
Why?
|
| Personality | 1 | 2018 | 560 | 0.030 |
Why?
|
| Cause of Death | 3 | 2003 | 3716 | 0.030 |
Why?
|
| Child | 17 | 2009 | 80668 | 0.030 |
Why?
|
| Nitrosourea Compounds | 1 | 1994 | 32 | 0.030 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1998 | 323 | 0.030 |
Why?
|
| Translating | 1 | 2015 | 144 | 0.030 |
Why?
|
| Stents | 2 | 1998 | 3193 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2018 | 797 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2002 | 1084 | 0.030 |
Why?
|
| Somatostatin | 1 | 1996 | 459 | 0.030 |
Why?
|
| New York | 2 | 2009 | 879 | 0.030 |
Why?
|
| Enzyme Induction | 2 | 2004 | 455 | 0.030 |
Why?
|
| Dietetics | 1 | 2013 | 34 | 0.030 |
Why?
|
| Prebiotics | 1 | 2013 | 41 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2021 | 1064 | 0.030 |
Why?
|
| MEDLINE | 1 | 2013 | 119 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2005 | 464 | 0.030 |
Why?
|
| Solutions | 2 | 2002 | 405 | 0.030 |
Why?
|
| Cell Line | 4 | 2012 | 15563 | 0.030 |
Why?
|
| Amino Acids | 2 | 2002 | 1711 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 1997 | 502 | 0.030 |
Why?
|
| Thiopental | 1 | 1993 | 55 | 0.030 |
Why?
|
| Statistics, Nonparametric | 3 | 2006 | 2846 | 0.030 |
Why?
|
| Stereotaxic Techniques | 2 | 2009 | 551 | 0.030 |
Why?
|
| Filgrastim | 2 | 2009 | 132 | 0.030 |
Why?
|
| Multiple Organ Failure | 2 | 2009 | 389 | 0.030 |
Why?
|
| Pelvic Bones | 1 | 1996 | 274 | 0.030 |
Why?
|
| Absorptiometry, Photon | 2 | 1998 | 1707 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 1995 | 17608 | 0.030 |
Why?
|
| Mass Screening | 1 | 2009 | 5454 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2001 | 1008 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 2 | 2009 | 895 | 0.030 |
Why?
|
| Halothane | 1 | 1993 | 200 | 0.030 |
Why?
|
| Colorectal Neoplasms | 2 | 2010 | 6962 | 0.030 |
Why?
|
| Histamine | 2 | 1985 | 496 | 0.030 |
Why?
|
| Patient Admission | 1 | 2000 | 1364 | 0.030 |
Why?
|
| Sodium Chloride | 2 | 2002 | 580 | 0.030 |
Why?
|
| Peroxidase | 3 | 2001 | 610 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2003 | 2030 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2002 | 2060 | 0.030 |
Why?
|
| Nitrous Oxide | 1 | 1993 | 166 | 0.030 |
Why?
|
| Benzamides | 2 | 2012 | 1375 | 0.030 |
Why?
|
| Neutrophils | 3 | 2001 | 3782 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2003 | 1787 | 0.030 |
Why?
|
| Nutrition Therapy | 1 | 2013 | 101 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2014 | 2921 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 1999 | 702 | 0.020 |
Why?
|
| Swine | 2 | 2007 | 5987 | 0.020 |
Why?
|
| Lymph Nodes | 3 | 1999 | 3468 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 1998 | 912 | 0.020 |
Why?
|
| Medicine | 2 | 2010 | 944 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 1995 | 911 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2006 | 3531 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1992 | 167 | 0.020 |
Why?
|
| Lactones | 2 | 2004 | 316 | 0.020 |
Why?
|
| Sensory System Agents | 1 | 2011 | 24 | 0.020 |
Why?
|
| Chlorambucil | 2 | 2007 | 42 | 0.020 |
Why?
|
| Emphysema | 1 | 1994 | 234 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 2 | 2004 | 596 | 0.020 |
Why?
|
| Caspase 3 | 2 | 2004 | 730 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 695 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 2885 | 0.020 |
Why?
|
| Transplantation, Heterologous | 3 | 2004 | 2391 | 0.020 |
Why?
|
| Procarbazine | 2 | 2007 | 172 | 0.020 |
Why?
|
| Oligopeptides | 1 | 1997 | 1195 | 0.020 |
Why?
|
| Gene Expression | 4 | 2010 | 7585 | 0.020 |
Why?
|
| Sweetening Agents | 1 | 2014 | 291 | 0.020 |
Why?
|
| Acupuncture Therapy | 1 | 1996 | 467 | 0.020 |
Why?
|
| Sulfones | 2 | 2004 | 447 | 0.020 |
Why?
|
| Outpatients | 1 | 2000 | 1596 | 0.020 |
Why?
|
| Virginia | 1 | 2011 | 115 | 0.020 |
Why?
|
| Cells, Cultured | 4 | 2012 | 18984 | 0.020 |
Why?
|
| Physician Executives | 1 | 2012 | 140 | 0.020 |
Why?
|
| Child, Preschool | 11 | 2009 | 42577 | 0.020 |
Why?
|
| Workflow | 1 | 2016 | 859 | 0.020 |
Why?
|
| Peer Review | 1 | 2013 | 218 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2014 | 354 | 0.020 |
Why?
|
| Pyridines | 1 | 2003 | 2888 | 0.020 |
Why?
|
| Ovarian Neoplasms | 2 | 2007 | 4904 | 0.020 |
Why?
|
| Arginine | 1 | 1995 | 932 | 0.020 |
Why?
|
| Wound Healing | 1 | 2002 | 2800 | 0.020 |
Why?
|
| Ribosomal Proteins | 2 | 2003 | 369 | 0.020 |
Why?
|
| Malignant Hyperthermia | 1 | 2011 | 72 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2001 | 1329 | 0.020 |
Why?
|
| Cost Savings | 1 | 2016 | 902 | 0.020 |
Why?
|
| Flow Cytometry | 3 | 2012 | 5890 | 0.020 |
Why?
|
| Fractures, Spontaneous | 1 | 1993 | 230 | 0.020 |
Why?
|
| Clinical Protocols | 2 | 2014 | 1437 | 0.020 |
Why?
|
| Endosonography | 2 | 2007 | 626 | 0.020 |
Why?
|
| Medicare | 3 | 2018 | 6820 | 0.020 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 1990 | 25 | 0.020 |
Why?
|
| Cross-Linking Reagents | 2 | 2004 | 689 | 0.020 |
Why?
|
| Risk | 4 | 2011 | 9602 | 0.020 |
Why?
|
| Polyethylenes | 1 | 1993 | 294 | 0.020 |
Why?
|
| Electrophysiology | 2 | 2002 | 1263 | 0.020 |
Why?
|
| Osteolysis | 1 | 1993 | 273 | 0.020 |
Why?
|
| Anesthesia, Obstetrical | 1 | 1993 | 234 | 0.020 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 161 | 0.020 |
Why?
|
| Embolism, Air | 1 | 2011 | 111 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1992 | 594 | 0.020 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1993 | 263 | 0.020 |
Why?
|
| Organizational Culture | 1 | 2014 | 513 | 0.020 |
Why?
|
| Cell Enlargement | 1 | 2010 | 58 | 0.020 |
Why?
|
| Comorbidity | 2 | 2018 | 10580 | 0.020 |
Why?
|
| Disease Management | 1 | 2001 | 2533 | 0.020 |
Why?
|
| Rural Population | 1 | 2021 | 2321 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 1997 | 766 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2000 | 1404 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2000 | 2948 | 0.020 |
Why?
|
| Darkness | 1 | 2010 | 159 | 0.020 |
Why?
|
| Algorithms | 4 | 2011 | 14072 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2005 | 3684 | 0.020 |
Why?
|
| Diaphragm | 1 | 2011 | 357 | 0.020 |
Why?
|
| Learning Curve | 1 | 2012 | 232 | 0.020 |
Why?
|
| Endoscopy | 1 | 2000 | 1854 | 0.020 |
Why?
|
| Cell Survival | 3 | 2004 | 5748 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 2009 | 6507 | 0.020 |
Why?
|
| Foreign Medical Graduates | 1 | 2010 | 76 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 1996 | 1350 | 0.020 |
Why?
|
| Dietary Fiber | 1 | 2013 | 767 | 0.020 |
Why?
|
| Probiotics | 1 | 2013 | 387 | 0.020 |
Why?
|
| Thymidylate Synthase | 1 | 2009 | 74 | 0.020 |
Why?
|
| Photoperiod | 1 | 2010 | 141 | 0.020 |
Why?
|
| Karnofsky Performance Status | 2 | 2003 | 163 | 0.020 |
Why?
|
| Vision Disorders | 1 | 1997 | 1090 | 0.020 |
Why?
|
| Cell Proliferation | 3 | 2012 | 10445 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1990 | 412 | 0.020 |
Why?
|
| Osteoporosis | 1 | 1999 | 1581 | 0.020 |
Why?
|
| Specialty Boards | 1 | 2011 | 235 | 0.020 |
Why?
|
| Muscle, Skeletal | 2 | 2003 | 4970 | 0.020 |
Why?
|
| Pain | 2 | 2002 | 5098 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1997 | 2605 | 0.020 |
Why?
|
| Quality Control | 1 | 2012 | 834 | 0.020 |
Why?
|
| New Jersey | 1 | 2009 | 296 | 0.020 |
Why?
|
| Acetic Acid | 1 | 1989 | 58 | 0.020 |
Why?
|
| Iliac Artery | 1 | 1990 | 344 | 0.020 |
Why?
|
| Health Services Research | 1 | 2016 | 1811 | 0.020 |
Why?
|
| Carmustine | 1 | 1988 | 137 | 0.020 |
Why?
|
| Organizational Policy | 1 | 2011 | 434 | 0.020 |
Why?
|
| Professional Competence | 1 | 2012 | 429 | 0.020 |
Why?
|
| GATA5 Transcription Factor | 1 | 2008 | 18 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 2815 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2012 | 360 | 0.020 |
Why?
|
| Myeloproliferative Disorders | 1 | 1994 | 616 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2015 | 2425 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2004 | 3587 | 0.020 |
Why?
|
| Biopsy | 3 | 2009 | 6779 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2009 | 615 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2008 | 93 | 0.020 |
Why?
|
| Dyspnea | 1 | 1996 | 1352 | 0.020 |
Why?
|
| Cell Movement | 3 | 2004 | 5199 | 0.020 |
Why?
|
| Reoperation | 1 | 1998 | 4325 | 0.020 |
Why?
|
| Cyclins | 1 | 2010 | 605 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2004 | 12150 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 1994 | 1274 | 0.020 |
Why?
|
| Animals, Newborn | 2 | 2003 | 2677 | 0.020 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 1988 | 61 | 0.020 |
Why?
|
| Liver | 4 | 2000 | 7571 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1988 | 321 | 0.020 |
Why?
|
| Piperazines | 2 | 2012 | 2547 | 0.020 |
Why?
|
| Aminopyrine | 1 | 1987 | 5 | 0.020 |
Why?
|
| Emergency Treatment | 1 | 2011 | 495 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2009 | 10384 | 0.020 |
Why?
|
| Marriage | 1 | 2009 | 351 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 3804 | 0.020 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2008 | 98 | 0.020 |
Why?
|
| Motivation | 2 | 2011 | 2020 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 1997 | 1456 | 0.020 |
Why?
|
| Sodium Bicarbonate | 1 | 1987 | 60 | 0.020 |
Why?
|
| Cell Adhesion | 2 | 2004 | 3093 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2010 | 352 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2008 | 175 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1997 | 3227 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1994 | 1194 | 0.020 |
Why?
|
| Sucrose | 1 | 1987 | 155 | 0.020 |
Why?
|
| Vagotomy, Proximal Gastric | 1 | 1986 | 8 | 0.020 |
Why?
|
| Life Tables | 2 | 2000 | 367 | 0.020 |
Why?
|
| Hypercalcemia | 1 | 1990 | 425 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2007 | 252 | 0.020 |
Why?
|
| Prevalence | 3 | 2010 | 15835 | 0.020 |
Why?
|
| Medroxyprogesterone | 1 | 1986 | 33 | 0.020 |
Why?
|
| Ifosfamide | 2 | 1999 | 233 | 0.020 |
Why?
|
| Intra-Abdominal Fat | 1 | 2011 | 624 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2006 | 31 | 0.020 |
Why?
|
| Proteins | 2 | 2002 | 6002 | 0.020 |
Why?
|
| Patient Compliance | 3 | 2007 | 2694 | 0.020 |
Why?
|
| RNA | 2 | 2008 | 2715 | 0.020 |
Why?
|
| Cricetulus | 1 | 2008 | 810 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 1996 | 1878 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2014 | 9661 | 0.020 |
Why?
|
| Keratin-7 | 1 | 2006 | 55 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2010 | 589 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 1993 | 1188 | 0.020 |
Why?
|
| Vagotomy, Truncal | 1 | 2005 | 10 | 0.020 |
Why?
|
| Depression | 1 | 2006 | 8228 | 0.020 |
Why?
|
| Dactinomycin | 2 | 1999 | 304 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 1384 | 0.020 |
Why?
|
| Pyrroles | 1 | 2012 | 1121 | 0.020 |
Why?
|
| Glycogen Synthase Kinases | 1 | 2005 | 40 | 0.020 |
Why?
|
| Neurons, Afferent | 1 | 2008 | 498 | 0.020 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1986 | 204 | 0.020 |
Why?
|
| Vascular Resistance | 2 | 1998 | 939 | 0.020 |
Why?
|
| CHO Cells | 1 | 2008 | 1376 | 0.020 |
Why?
|
| Prolactinoma | 1 | 2006 | 114 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 1405 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 2009 | 442 | 0.020 |
Why?
|
| Flurbiprofen | 1 | 1985 | 21 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2006 | 362 | 0.020 |
Why?
|
| Gastritis | 1 | 1987 | 199 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 1917 | 0.020 |
Why?
|
| Urea | 1 | 1987 | 449 | 0.020 |
Why?
|
| Health Status | 2 | 2013 | 4087 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2007 | 562 | 0.020 |
Why?
|
| Genes, src | 1 | 2004 | 51 | 0.010 |
Why?
|
| Ephrin-A1 | 1 | 2004 | 9 | 0.010 |
Why?
|
| Intercellular Junctions | 1 | 1985 | 198 | 0.010 |
Why?
|
| Bilirubin | 2 | 2000 | 439 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 10264 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2012 | 2931 | 0.010 |
Why?
|
| Swine, Miniature | 1 | 2007 | 972 | 0.010 |
Why?
|
| Emergencies | 1 | 2011 | 1223 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 1885 | 0.010 |
Why?
|
| Cholangiography | 1 | 1985 | 182 | 0.010 |
Why?
|
| Physiology | 1 | 1985 | 112 | 0.010 |
Why?
|
| Gastric Fundus | 1 | 1984 | 37 | 0.010 |
Why?
|
| Vitronectin | 1 | 2004 | 40 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2007 | 612 | 0.010 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2004 | 65 | 0.010 |
Why?
|
| Partial Pressure | 1 | 1984 | 247 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1997 | 5143 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 693 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 2 | 1999 | 228 | 0.010 |
Why?
|
| Eye Proteins | 1 | 2008 | 628 | 0.010 |
Why?
|
| Ribavirin | 1 | 2006 | 396 | 0.010 |
Why?
|
| Jaundice | 1 | 1985 | 95 | 0.010 |
Why?
|
| Cesarean Section | 1 | 1993 | 1418 | 0.010 |
Why?
|
| Zollinger-Ellison Syndrome | 1 | 1984 | 13 | 0.010 |
Why?
|
| Receptor, EphB3 | 1 | 2003 | 11 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2006 | 618 | 0.010 |
Why?
|
| Electrodes | 2 | 2000 | 610 | 0.010 |
Why?
|
| Propionates | 1 | 1985 | 180 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2004 | 186 | 0.010 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2004 | 74 | 0.010 |
Why?
|
| Anaphylaxis | 1 | 2011 | 738 | 0.010 |
Why?
|
| Biliary Tract | 1 | 1985 | 136 | 0.010 |
Why?
|
| Receptor, erbB-2 | 2 | 2006 | 2597 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 1988 | 426 | 0.010 |
Why?
|
| Vinculin | 1 | 2003 | 58 | 0.010 |
Why?
|
| Inflammation | 3 | 2000 | 10860 | 0.010 |
Why?
|
| Oncogene Protein v-akt | 1 | 2004 | 130 | 0.010 |
Why?
|
| Self Report | 1 | 2015 | 3771 | 0.010 |
Why?
|
| Quinones | 1 | 2003 | 79 | 0.010 |
Why?
|
| Mathematics | 1 | 1985 | 696 | 0.010 |
Why?
|
| Rifabutin | 1 | 2003 | 53 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 2004 | 182 | 0.010 |
Why?
|
| Genistein | 1 | 2003 | 87 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2004 | 118 | 0.010 |
Why?
|
| Indoles | 1 | 2012 | 1834 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2004 | 173 | 0.010 |
Why?
|
| Patient Care | 1 | 2009 | 629 | 0.010 |
Why?
|
| Lentivirus | 1 | 2006 | 518 | 0.010 |
Why?
|
| Alkaline Phosphatase | 2 | 2000 | 855 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 2004 | 270 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2004 | 313 | 0.010 |
Why?
|
| Gastroscopy | 1 | 1985 | 213 | 0.010 |
Why?
|
| Brunner Glands | 1 | 2003 | 11 | 0.010 |
Why?
|
| Hyperemia | 1 | 1985 | 223 | 0.010 |
Why?
|
| Omeprazole | 1 | 1984 | 106 | 0.010 |
Why?
|
| Pituitary Irradiation | 1 | 2002 | 14 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 1131 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1985 | 527 | 0.010 |
Why?
|
| Benzoquinones | 1 | 2003 | 198 | 0.010 |
Why?
|
| Nitrogen | 1 | 1984 | 344 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2004 | 281 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 1189 | 0.010 |
Why?
|
| Leiomyoma | 1 | 1988 | 644 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 1365 | 0.010 |
Why?
|
| Phospholipids | 1 | 1987 | 778 | 0.010 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1984 | 304 | 0.010 |
Why?
|
| Gallbladder Diseases | 1 | 1984 | 139 | 0.010 |
Why?
|
| Neoplasm Proteins | 2 | 2006 | 3601 | 0.010 |
Why?
|
| Laminin | 1 | 2004 | 404 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2003 | 285 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 411 | 0.010 |
Why?
|
| Massachusetts | 1 | 2015 | 8891 | 0.010 |
Why?
|
| Luciferases | 1 | 2004 | 713 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1991 | 1163 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2004 | 255 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 361 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2004 | 287 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 610 | 0.010 |
Why?
|
| Isotonic Solutions | 2 | 1996 | 119 | 0.010 |
Why?
|
| Thymidine | 1 | 2002 | 297 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 319 | 0.010 |
Why?
|
| Myosin Light Chains | 1 | 2002 | 121 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2003 | 1141 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 615 | 0.010 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2004 | 385 | 0.010 |
Why?
|
| Lactams, Macrocyclic | 1 | 2003 | 319 | 0.010 |
Why?
|
| Health Services Accessibility | 2 | 2010 | 5514 | 0.010 |
Why?
|
| Cachexia | 1 | 2003 | 202 | 0.010 |
Why?
|
| Retroviridae | 1 | 2004 | 846 | 0.010 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 1026 | 0.010 |
Why?
|
| Tritium | 1 | 2002 | 707 | 0.010 |
Why?
|
| Androstadienes | 1 | 2003 | 348 | 0.010 |
Why?
|
| Medical Audit | 1 | 2003 | 454 | 0.010 |
Why?
|
| Bile | 1 | 2002 | 300 | 0.010 |
Why?
|
| Critical Care | 1 | 2014 | 2714 | 0.010 |
Why?
|
| Prednisolone | 2 | 1993 | 326 | 0.010 |
Why?
|
| Cold Temperature | 1 | 2005 | 794 | 0.010 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2003 | 219 | 0.010 |
Why?
|
| Transplants | 1 | 2003 | 209 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2011 | 2258 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2004 | 855 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 1062 | 0.010 |
Why?
|
| 3-O-Methylglucose | 1 | 2001 | 37 | 0.010 |
Why?
|
| Serine | 1 | 2005 | 828 | 0.010 |
Why?
|
| Home Infusion Therapy | 1 | 2001 | 18 | 0.010 |
Why?
|
| Guanosine | 1 | 2001 | 43 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 2127 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2004 | 633 | 0.010 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1995 | 2429 | 0.010 |
Why?
|
| Infant | 5 | 2009 | 36461 | 0.010 |
Why?
|
| Family Health | 1 | 2006 | 1254 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2002 | 514 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2013 | 3208 | 0.010 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2000 | 36 | 0.010 |
Why?
|
| Esophagectomy | 1 | 2004 | 478 | 0.010 |
Why?
|
| Medicaid | 1 | 2014 | 2836 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2008 | 2093 | 0.010 |
Why?
|
| Etoposide | 2 | 1993 | 638 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1985 | 1986 | 0.010 |
Why?
|
| Cell Size | 1 | 2002 | 625 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1697 | 0.010 |
Why?
|
| Benchmarking | 1 | 2007 | 1056 | 0.010 |
Why?
|
| Mycobacterium | 1 | 2002 | 252 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2001 | 361 | 0.010 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 1086 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2007 | 1276 | 0.010 |
Why?
|
| Cell Count | 1 | 2004 | 1826 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 2214 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2000 | 816 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2000 | 310 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2004 | 1756 | 0.010 |
Why?
|
| Phenols | 1 | 2003 | 526 | 0.010 |
Why?
|
| Human Growth Hormone | 1 | 2004 | 640 | 0.010 |
Why?
|
| Mammals | 1 | 2005 | 1133 | 0.010 |
Why?
|
| Syndrome | 1 | 2006 | 3271 | 0.010 |
Why?
|
| Tyrosine | 1 | 2004 | 1425 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1987 | 1406 | 0.010 |
Why?
|
| Gastrectomy | 1 | 2004 | 693 | 0.010 |
Why?
|
| Fibrosis | 2 | 1999 | 2077 | 0.010 |
Why?
|
| Arteries | 1 | 1984 | 1123 | 0.010 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2002 | 314 | 0.010 |
Why?
|
| Consciousness | 1 | 1985 | 602 | 0.010 |
Why?
|
| Protein Transport | 1 | 2005 | 1942 | 0.010 |
Why?
|
| Genes, ras | 1 | 2002 | 656 | 0.010 |
Why?
|
| Diet | 2 | 2011 | 8088 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2000 | 337 | 0.010 |
Why?
|
| Drug Resistance, Viral | 1 | 2004 | 868 | 0.010 |
Why?
|
| Osmolar Concentration | 2 | 1992 | 655 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 1892 | 0.010 |
Why?
|
| Infection Control | 1 | 2006 | 984 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 2001 | 0.010 |
Why?
|
| Complement Activation | 1 | 2001 | 447 | 0.010 |
Why?
|
| Tape Recording | 1 | 1998 | 77 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 2430 | 0.010 |
Why?
|
| Family | 1 | 2009 | 3209 | 0.010 |
Why?
|
| Platinum | 1 | 2000 | 219 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 1984 | 862 | 0.010 |
Why?
|
| Punctures | 1 | 2000 | 371 | 0.010 |
Why?
|
| Anxiety | 2 | 2004 | 4670 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 877 | 0.010 |
Why?
|
| Pregnancy | 3 | 2007 | 30237 | 0.010 |
Why?
|
| Ethionine | 1 | 1997 | 10 | 0.010 |
Why?
|
| Insulin | 1 | 2012 | 6608 | 0.010 |
Why?
|
| Electric Impedance | 1 | 2002 | 791 | 0.010 |
Why?
|
| Respiration | 1 | 1984 | 1654 | 0.010 |
Why?
|
| Life Style | 1 | 2009 | 3926 | 0.010 |
Why?
|
| Choline Deficiency | 1 | 1997 | 23 | 0.010 |
Why?
|
| Esophagus | 1 | 1984 | 1040 | 0.010 |
Why?
|
| Glioblastoma | 2 | 1993 | 3458 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 2826 | 0.010 |
Why?
|
| Weight Gain | 1 | 2008 | 2356 | 0.010 |
Why?
|
| Clonazepam | 1 | 1997 | 135 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2006 | 4860 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2004 | 1069 | 0.010 |
Why?
|
| Organ Size | 1 | 2002 | 2261 | 0.010 |
Why?
|
| Adolescent Behavior | 1 | 2006 | 1184 | 0.010 |
Why?
|
| Frozen Sections | 1 | 1998 | 153 | 0.010 |
Why?
|
| Mesenteric Artery, Superior | 1 | 1997 | 96 | 0.010 |
Why?
|
| Phenytoin | 1 | 1997 | 189 | 0.010 |
Why?
|
| Busulfan | 1 | 1997 | 264 | 0.010 |
Why?
|
| Lung | 3 | 2001 | 10067 | 0.010 |
Why?
|
| Abdomen, Acute | 1 | 1997 | 122 | 0.010 |
Why?
|
| Asparaginase | 1 | 1998 | 240 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2001 | 1889 | 0.010 |
Why?
|
| Myositis Ossificans | 1 | 1997 | 77 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1998 | 387 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 1998 | 294 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 2971 | 0.010 |
Why?
|
| Devazepide | 1 | 1996 | 4 | 0.010 |
Why?
|
| Receptors, Cholecystokinin | 1 | 1996 | 18 | 0.010 |
Why?
|
| Actins | 1 | 2004 | 2060 | 0.010 |
Why?
|
| Digestion | 1 | 1996 | 53 | 0.010 |
Why?
|
| Benzodiazepinones | 1 | 1996 | 50 | 0.010 |
Why?
|
| Telephone | 1 | 2000 | 629 | 0.010 |
Why?
|
| Cytarabine | 1 | 1998 | 696 | 0.010 |
Why?
|
| Buffers | 1 | 1996 | 141 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1996 | 395 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 2839 | 0.010 |
Why?
|
| Melphalan | 1 | 1997 | 425 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 1997 | 316 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 2493 | 0.010 |
Why?
|
| Hormone Antagonists | 1 | 1996 | 109 | 0.010 |
Why?
|
| Acupuncture Points | 1 | 1996 | 104 | 0.010 |
Why?
|
| Heart | 1 | 2009 | 4425 | 0.010 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 1997 | 221 | 0.010 |
Why?
|
| Perception | 1 | 2002 | 1204 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1997 | 299 | 0.010 |
Why?
|
| Cutaneous Fistula | 1 | 1995 | 79 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2004 | 2870 | 0.010 |
Why?
|
| Enterobacter | 1 | 1994 | 44 | 0.010 |
Why?
|
| Carcinoma, Large Cell | 1 | 1995 | 114 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1996 | 544 | 0.010 |
Why?
|
| Endocrine Glands | 1 | 1994 | 101 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2000 | 1392 | 0.010 |
Why?
|
| Professional-Patient Relations | 1 | 2000 | 724 | 0.010 |
Why?
|
| Fistula | 1 | 1996 | 213 | 0.010 |
Why?
|
| Health Care Reform | 1 | 2003 | 1256 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 2631 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1995 | 266 | 0.010 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1997 | 335 | 0.010 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 1994 | 111 | 0.010 |
Why?
|
| Streptococcus | 1 | 1994 | 197 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2002 | 1895 | 0.010 |
Why?
|
| Anesthesia | 1 | 1985 | 1595 | 0.010 |
Why?
|
| Decompression, Surgical | 1 | 1999 | 603 | 0.010 |
Why?
|
| Neurosecretory Systems | 1 | 1995 | 223 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2006 | 3070 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1994 | 405 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1994 | 861 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 2000 | 939 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 16724 | 0.010 |
Why?
|
| Regeneration | 1 | 2002 | 1520 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2007 | 6259 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 2003 | 1380 | 0.010 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 1997 | 488 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1995 | 1305 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1995 | 309 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1995 | 638 | 0.010 |
Why?
|
| Papaverine | 1 | 1992 | 44 | 0.010 |
Why?
|
| Glucagon | 1 | 1995 | 534 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 3439 | 0.010 |
Why?
|
| Serous Membrane | 1 | 1992 | 22 | 0.010 |
Why?
|
| Endocrine System Diseases | 1 | 1994 | 247 | 0.010 |
Why?
|
| Neurilemmoma | 1 | 1997 | 522 | 0.010 |
Why?
|
| Mental Recall | 1 | 1998 | 1218 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1997 | 904 | 0.010 |
Why?
|
| Feedback | 1 | 1996 | 797 | 0.010 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1998 | 1205 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 1991 | 129 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1993 | 234 | 0.010 |
Why?
|
| Nervous System | 1 | 1994 | 542 | 0.010 |
Why?
|
| Spine | 1 | 1998 | 1134 | 0.010 |
Why?
|
| Menopause | 2 | 1991 | 1657 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 1997 | 1635 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 1996 | 978 | 0.010 |
Why?
|
| Cost Control | 1 | 1993 | 628 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1992 | 416 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 668 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 1997 | 1827 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1998 | 1838 | 0.010 |
Why?
|
| Longitudinal Studies | 2 | 1999 | 14762 | 0.010 |
Why?
|
| Radioisotope Teletherapy | 1 | 1988 | 15 | 0.000 |
Why?
|
| Pressure | 1 | 1992 | 1172 | 0.000 |
Why?
|
| Awareness | 1 | 1993 | 653 | 0.000 |
Why?
|
| Mutation | 2 | 2004 | 30213 | 0.000 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 4652 | 0.000 |
Why?
|
| California | 1 | 1993 | 1435 | 0.000 |
Why?
|
| Atrophy | 1 | 1993 | 1631 | 0.000 |
Why?
|
| Employment | 1 | 1994 | 1110 | 0.000 |
Why?
|
| Leukopenia | 1 | 1988 | 213 | 0.000 |
Why?
|
| Reactive Oxygen Species | 1 | 1996 | 2142 | 0.000 |
Why?
|
| Tin | 1 | 1987 | 13 | 0.000 |
Why?
|
| Anticonvulsants | 1 | 1997 | 1921 | 0.000 |
Why?
|
| Potentiometry | 1 | 1987 | 10 | 0.000 |
Why?
|
| Biological Transport, Active | 1 | 1987 | 323 | 0.000 |
Why?
|
| Educational Status | 1 | 1994 | 2510 | 0.000 |
Why?
|
| Pentagastrin | 1 | 1986 | 17 | 0.000 |
Why?
|
| Salts | 1 | 1987 | 60 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 9611 | 0.000 |
Why?
|
| Stimulation, Chemical | 1 | 1986 | 305 | 0.000 |
Why?
|
| Endothelium, Vascular | 1 | 1998 | 4424 | 0.000 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1986 | 153 | 0.000 |
Why?
|
| Radioisotopes | 1 | 1987 | 509 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1992 | 1497 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 5861 | 0.000 |
Why?
|
| Mortality | 1 | 1996 | 2910 | 0.000 |
Why?
|
| Aging | 1 | 2003 | 8731 | 0.000 |
Why?
|
| Seizures | 1 | 1997 | 2996 | 0.000 |
Why?
|
| Capillary Permeability | 1 | 1988 | 772 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 11094 | 0.000 |
Why?
|
| Registries | 1 | 2000 | 8351 | 0.000 |
Why?
|
| Respiration Disorders | 1 | 1986 | 364 | 0.000 |
Why?
|
| Emotions | 1 | 1994 | 2758 | 0.000 |
Why?
|
| Edema | 1 | 1986 | 764 | 0.000 |
Why?
|
| Gadolinium | 1 | 1987 | 964 | 0.000 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1988 | 934 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1988 | 2926 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1985 | 8045 | 0.000 |
Why?
|